Asher Bio Entered into a Clinical Trial Collaboration with Merck to Evaluate AB248 + Keytruda (pembrolizumab) for Locally Advanced or Metastatic Solid Tumors
Shots:
- The companies collaborated to initiate a P-Ia/Ib dose-escalation & expansion trial to evaluate AB248 (CD8-targeted IL-2) as monothx. & in combination with Keytruda in patients with LA or metastatic solid tumors including melanoma, RCC, NSCLC & SCCHN. The trial is expected to initiate in H2’22
- In the preclinical studies, AB248 had strong anti-tumor activity as monothx. & in combination with anti-PD1 with no toxicity or weight loss. Furthermore, treatment with a "not" IL-2 resulted in decreased anti-tumor efficacy & body weight loss
- In other nonclinical studies, AB248 showed potent anti-tumor activity in murine tumor models. AB248 is a novel CD8+ T cell-selective IL-2 that was created by combining a low-potency IL-2 mutein with a humanized IgG1 anti-CD8 Ab
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
